In addition, enhancer of zeste homolog 2 (EZH2) inhibitors are new drugs for the treatment of cancers lacking SMARCB1, and preclinical studies have shown that they have the potential to modulate tumor immunogenicity and antitumor immune responses (57). Here, SMARCB1 is linked to neoplasm.